Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells

Journal of the National Cancer Institute

Volumn 94, Issue 8, 2002, Pages 617-629

  Syed, Viqar ^a   Ulinski, Gregory ^b   Mok, Samuel C ^c   Ho, Shuk Mei ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b WORCESTER POLYTECHNIC INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; CELL PROTEIN; ESTRADIOL; ESTRONE; FOLLITROPIN; GONADOTROPIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LUTEINIZING HORMONE; MESSENGER RNA; NEUTRALIZING ANTIBODY; SEX HORMONE; STAT3 PROTEIN; TESTOSTERONE;

ADULT; ALPHA CHAIN; ARTICLE; CANCER CELL CULTURE; CANCER RISK; CELL IMMORTALIZATION; CELL PROLIFERATION; COLONY FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; WILD TYPE;

EID: 0037123348     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.8.617     Document Type: Article

References (66)

1. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone
2. Ovarian surface epithelium: Biology, endocrinology, and pathology
3. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer
4. Estrogen replacement therapy and fatal ovarian cancer
5. Human menopausal gonadotropin and the risk of epithelial ovarian cancer
6. Estrogen action in human ovarian cancer
7. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis
8. Serum gonadotropins and steroid hormones and the development of ovarian cancer
9. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer
10. Estrogen replacement therapy and ovarian cancer
11. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women
12. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells
13. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube
14. Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas
15. Review: Gonadotropins and development of ovarian cancer
16. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone
17. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells
18. Hormonal carcinogenesis
19. The interleukin-6 cytokine system in embryonic development, embryo-maternal interactions and cardiogenesis
20. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6
21. Interleukin-6 signal transduction and lymphocyte function
22. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas
23. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells
24. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro
25. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications
26. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma
27. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway
28. Interleukin-6 and prostate cancer progression
29. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor
30. Interleukin 6 and its receptor: Ten years later
31. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway
32. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
33. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
34. STATs in oncogenesis
35. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures
36. Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells
37. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer
38. Interleukin-6 serum levels in patients with gynecological tumors
39. Serum evaluation of interleukin 6 in ovarian cancer patients
40. Cytokine-mediated modulation of cisplatin sensitivity in ovarian cancer cells
41. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel
42. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer
43. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma
44. Gonadotropins induce the release of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha from the human preovulatory follicle
45. Ovarian production of IL6 and its potential inhibitory effect on progesterone secretion in Cynomolgus fascicularis
46. Regulation of Sertoli cell IL-1 and IL-6 production in vitro
47. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor
48. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: Down-regulation with essential fatty acids, ethanol and pentoxifylline
49. The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line
50. Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro
51. Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors
52. Effect of estrogen and progesterone on gene expression of growth regulatory molecules and proto-oncogene in vascular smooth muscle cells
53. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the anti-osteoporotic effect of estrogens
54. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines
55. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs)
56. Reactivity of a monoclonal antibody with human ovarian carcinoma
57. Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction
58. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs
59. STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription
60. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells
61. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts
62. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
63. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP
64. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors
65. Stat3 as an oncogene
66. Steroid release from two human epithelial ovarian tumors: Evidence for an intrinsic production in vitro